Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00999466
First received: October 20, 2009
Last updated: December 21, 2011
Last verified: December 2011

October 20, 2009
December 21, 2011
October 2009
February 2011   (final data collection date for primary outcome measure)
FEV1, Late Asthmatic Response (LAR) [ Time Frame: Measured 1 week and 4 weeks after last dose. ] [ Designated as safety issue: No ]
FEV1, Late Asthmatic Response (LAR) [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00999466 on ClinicalTrials.gov Archive Site
  • FEV1, Early Asthmatic Response (EAR) [ Time Frame: Measured. 1 week and 4 weeks after last dose. ] [ Designated as safety issue: No ]
  • PC20 Methacholine Challenge - Bronchial Hyperreactivity measured by FEV1 [ Time Frame: Measured at 2 occasions pre-treatment (within 8 weeks of randomisation) and at 4 occasions post treatment (2-3 days before and 1 day +/- 6 hours after both allergen challenges). ] [ Designated as safety issue: No ]
  • Sputum Cellularity and Cytokines - Sputum Biomarkers. [ Time Frame: Measured at 2 occasions pre-treatment (within 8 weeks of randomisation) and at 4 occasions post treatment (2-3 days before and 1 day +/- 6 hours after both allergen challenges). ] [ Designated as safety issue: No ]
  • FEV1, Early Asthmatic Response (EAR) [ Designated as safety issue: No ]
  • PC20 Methacholine Challenge - Bronchial Hyperreactivity measured by FEV1 [ Designated as safety issue: No ]
  • Sputum Cellularity and Cytokines - Sputum Biomarkers. [ Designated as safety issue: No ]
Not Provided
Not Provided
 
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
A Double-blind, Placebo-controlled, Randomised, Parallel Group, Phase IIa Study to Investigate the Efficacy, Tolerability and Safety of 8 Doses of AZD8848 Administered Intranasally Once Weekly in Mild to Moderate Allergic Asthma Subjects Challenged With an Inhaled Allergen.

AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total. The first part will investigate the tolerability and safety of AZD8848 while the second part will investigate both the therapeutic effect of AZD8848 and how well patients tolerate the drug.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Allergic Asthma
  • Drug: AZD8848
    Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
  • Drug: Placebo
    Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
  • Experimental: 1
    AZD8848 (30 μg PILOT part and 60 μg MAIN part)
    Intervention: Drug: AZD8848
  • Placebo Comparator: 2
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
61
December 2011
February 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • FEV1 > 70 % of predicted normal pre-bronchodilator
  • Documented history of asthma
  • Presence of allergic sensitivity

Exclusion Criteria:

  • Clinically relevant disease and/or abnormality (past or present), which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study.
  • Symptomatic allergic rhinitis
  • Any clinical relevant abnormal findings in physical examination or assessment which may put the patient at risk because of participation in the study
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00999466
D0540C00004
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Leif Eriksson, MD AstraZeneca R&D Lund
Principal Investigator: Brian Leaker, MD Respiratory Clinical Trials
AstraZeneca
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP